JOHNSON JOHN sold $91K of XERS
JOHNSON JOHN sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $6.09 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Provides a datapoint on director selling activity; however, 10b5-1 pre-arrangement reduces interpretive weight for trading decisions.
Market read
Traders may monitor for patterns of insider activity, but this specific filing is unlikely to be a standalone catalyst.
What to watch
10b5-1 plans are often scheduled regardless of near-term fundamentals; the sale price may reflect timing rather than conviction.
Background
The article is an SEC Form 4 insider transaction disclosure for Xeris Biopharma Holdings, Inc.
Ticker impact
Xeris Biopharma disclosed a director open-market sale of 15,000 shares at ~$6.09 on a 10b5-1 plan via SEC Form 4.
Low near-term impact; any move is likely dominated by broader biotech/news flow rather than this Form 4.
The filing is a routine 10b5-1 sale with a disclosed price and size, providing limited incremental fundamental information.
Market effects
Minimal; single-company insider transaction with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
If the market interprets the sale as risk-reduction despite 10b5-1, it could modestly worsen sentiment versus peers.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the SEC Form 4 insider transaction (director open-market sale).
- directorJOHNSON JOHN
Director who sold 15,000 shares under a pre-arranged 10b5-1 plan.
